The stock of InVitae Corp (NYSE:NVTA) is a huge mover today! The stock increased 8.99% or $0.62 on November 7, hitting $7.52. About 82,957 shares traded hands or 22.79% up from the average. InVitae Corp (NYSE:NVTA) has declined 36.23% since April 5, 2016 and is downtrending. It has underperformed by 38.19% the S&P500.
The move comes after 7 months positive chart setup for the $218.14 million company. It was reported on Nov, 7 by Barchart.com. We have $20.98 PT which if reached, will make NYSE:NVTA worth $390.47 million more.
InVitae Corp (NYSE:NVTA) Ratings Coverage
Out of 3 analysts covering Invitae (NYSE:NVTA), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Invitae has been the topic of 3 analyst reports since August 14, 2015 according to StockzIntelligence Inc. The company was initiated on Friday, August 14 by William Blair. The stock of InVitae Corp (NYSE:NVTA) has “Overweight” rating given on Tuesday, August 9 by JP Morgan. Leerink Swann downgraded InVitae Corp (NYSE:NVTA) on Thursday, January 28 to “Mkt Perform” rating.
According to Zacks Investment Research, “Invitae Corporation is engaged in genetic diagnostics for hereditary disorders which include breast, colon and pancreatic cancer. It operates primarily in the United States, Israel and internationally. Invitae Corporation is headquartered in San Francisco, California.”
More news for InVitae Corp (NYSE:NVTA) were recently published by: Bizjournals.com, which released: “EXCLUSIVE: DNA testing giant leases entire Potrero Hill redevelopment site” on September 22, 2015. Reuters.com‘s article titled: “BRIEF-Invitae Corp entered into a provider agreement for laboratory servic…” and published on September 13, 2016 is yet another important article.
NVTA Company Profile
Invitae Corporation (Invitae), incorporated on January 13, 2010, utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. The Company’s laboratory is located in San Francisco, California. The Company’s product is an assay of over 600 genes that can be used for multiple indications. The test includes multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders and other hereditary conditions.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.